12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aveed regulatory update

FDA's Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committees will meet on April 18 to discuss a resubmitted NDA from Endo for Aveed testosterone undecanoate to treat male hypogonadism. Endo...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >